Nanthealth LLC (NYSE:NH) fell 5.5% on Thursday . The company traded as low as $12.26 and last traded at $12.39, with a volume of 74,158 shares changing hands. The stock had previously closed at $13.11.

A number of brokerages recently weighed in on NH. First Analysis began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set an “overweight” rating and a $18.00 price objective for the company. FBR & Co reaffirmed a “buy” rating on shares of Nanthealth in a research report on Wednesday, August 10th. Canaccord Genuity began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set a “buy” rating and a $17.00 price objective for the company. Jefferies Group began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set a “buy” rating for the company. Finally, Cowen and Company began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set an “outperform” rating and a $19.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.00.

The company has a 50-day moving average of $11.44 and a 200-day moving average of $12.41. The stock’s market capitalization is $1.51 billion.

Nanthealth (NYSE:NH) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.26. The firm had revenue of $31.50 million for the quarter, compared to the consensus estimate of $23.55 million. The firm’s quarterly revenue was up 166.9% on a year-over-year basis. On average, equities analysts forecast that Nanthealth LLC will post ($0.63) earnings per share for the current year.

In related news, CEO Patrick Soon-Shiong purchased 357,143 shares of Nanthealth stock in a transaction on Tuesday, June 7th. The stock was purchased at an average cost of $14.00 per share, with a total value of $5,000,002.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Healthcare Solution Allscripts purchased 714,286 shares of Nanthealth stock in a transaction on Tuesday, June 7th. The stock was bought at an average cost of $14.00 per share, with a total value of $10,000,004.00. Following the completion of the acquisition, the insider now owns 15,000,000 shares in the company, valued at $210,000,000. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.